Oppenheimer analyst Owen Lau maintains Focus Finl Partners (NASDAQ:FOCS) with a Outperform and lowers the price target from $60 to $52.
Abeona Therapeutics Provides Regulatory Update On Pz-cel; CRL Did Not Identify Deficiencies Related To Clinical Efficacy Or Clinical Safety Data In BLA, And No New Clinical Studies Requested By FDA To Support Approval
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies